High stability of yellow fever 17D-204 vaccine:: A 12-year restrospective analysis of large-scale production

被引:50
作者
Barban, V.
Girerd, Y.
Aguirre, A.
Gulia, S.
Petiard, F.
Riou, P.
Barrere, B.
Lang, J.
机构
[1] Sanofi Pasteur, Dept Res, F-69680 Marcy Letoile, France
[2] Sanofi Pasteur, Qual Control Dev, F-69680 Marcy Letoile, France
关键词
yellow fever vaccine; virus stability; vaccine characterization;
D O I
10.1016/j.vaccine.2006.06.082
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have retrospectively analyzed 12 bulk lots of yellow fever vaccine Stamaril (TM), produced between 1990 and 2002 and prepared from the same seed lot that has been in continuous Use since 1990. All vaccine batches displayed identical genome sequence. Only four nucleotide substitutions were observed, compared to previously published sequence, with no incidence at amino-acid level. Fine analysis of viral plaque size distribution was used as an additional marker for genetic stability and demonstrated a remarkable homogeneity of the viral population. The total virus load, measured by qRT-PCR, was also homogeneous pointing out reproducibility of the vaccine production process. Mice inoculated intracerebrally with the different bulks exhibited a similar average survival time, and ratio between in vitro potency and mouse LD50 titers remained constant from batch-to-batch. Taken together, these data demonstrate the genetic stability of the strain at mass production level over a period of 12 years and reinforce the generally admitted idea of the safety of YF17D-based vaccines. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2941 / 2950
页数:10
相关论文
共 37 条
[1]  
Adhiyaman V, 2001, LANCET, V358, P1907, DOI 10.1016/S0140-6736(01)06914-8
[2]  
[Anonymous], VACCINES
[3]   Yellow fever vaccine safety: a reality or a myth? [J].
Arya, SC .
VACCINE, 2002, 20 (31-32) :3627-3628
[4]   COMPARISON OF NEUROVIRULENCE OF DIFFERENT STRAINS OF YELLOW-FEVER VIRUS IN MICE [J].
BARRETT, ADT ;
GOULD, EA .
JOURNAL OF GENERAL VIROLOGY, 1986, 67 :631-637
[5]  
DOSSANTOS CND, 1995, VIRUS RES, V35, P35
[6]   NUCLEOTIDE-SEQUENCE COMPARISON OF THE GENOME OF 2 17D-204 YELLOW-FEVER VACCINES [J].
DUPUY, A ;
DESPRES, P ;
CAHOUR, A ;
GIRARD, M ;
BOULOY, M .
NUCLEIC ACIDS RESEARCH, 1989, 17 (10) :3989-3989
[7]   History of thymoma and yellow fever vaccination [J].
Eidex, RB .
LANCET, 2004, 364 (9438) :936-936
[8]   Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine [J].
Ferguson, M ;
Heath, A .
BIOLOGICALS, 2004, 32 (04) :195-205
[9]   Behavior of 17D yellow fever virus in rhesus monkeys - Relation to substrain, dose and neural or extraneural inoculation [J].
Fox, JP ;
Penna, HA .
AMERICAN JOURNAL OF HYGIENE, 1943, 38 (02) :152-172
[10]   Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil [J].
Galler, R ;
Pugachev, KV ;
Santos, CLS ;
Ocran, SW ;
Jabor, AV ;
Rodrigues, SG ;
Marchevsky, RS ;
Freire, MS ;
Almeida, LFC ;
Cruz, ACR ;
Yamamura, AMY ;
Rocco, IM ;
da Rosa, EST ;
Souza, LTM ;
Vasconcelos, PFC ;
Guirakhoo, F ;
Monath, TP .
VIROLOGY, 2001, 290 (02) :309-319